Hormonal treatment of advanced serous borderline ovarian tumours: four patients with response to hormonal therapy

 

Authors

  • C. Pisano Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • F. Magazzino Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • S. Greggi Division of Gynaecology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • S. Losito Division of Pathology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • R. Franco Division of Pathology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • M. Di Napoli Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • S. Cecere Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • C. Cavaliere Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • G. Facchini Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • R. Tambaro Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
  • S. Pignata Division of Medical Oncology, Department of Gynaecologic and Urologic Surgery and Oncology, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.

Keywords:

borderline ovarian tumours, tamoxifen

Abstract

Treatment of advanced or recurrent borderline ovarian tumours is mainly surgery-based while the results of chemotherapy are unsatisfactory. The majority of borderline ovarian tumours express oestrogen receptors and few cases of response to various hormonal treatments have been reported. We describe four cases of recurrent borderline ovarian tumours expressing oestrogen receptors that were successfully treated with tamoxifen 20 mg/daily. In no case did we observe a complete remission of the disease, but in all cases a clinical and serological response was observed. In one patient, disease control was maintained for several years. In one case, after progression during tamoxifen treatment, a response was achieved with a doubling of the tamoxifen dose. Two out of 4 patients are alive on tamoxifen treatment and in remission from 10 and 15 months, respectively. In conclusion, these data support the hypothesis that hormonal treatment represents a useful option for recurrent borderline ovarian tumours.

Downloads

Published

2013-10-15

How to Cite

1.
Pisano C, Magazzino F, Greggi S, Losito S, Franco R, Di Napoli M, Cecere S, Cavaliere C, Facchini G, Tambaro R, Pignata S. Hormonal treatment of advanced serous borderline ovarian tumours: four patients with response to hormonal therapy:  . CBN [Internet]. 2013 Oct. 15 [cited 2024 Dec. 4];1(1):18-21. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/250

Issue

Vol. 1 No. 1 (2013): January - December 2013

Section

Clinical original article

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.